Survodutide

Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim that has shown particularly impressive results for liver fat reduction and metabolic-associated steatohepatitis (MASH/NASH). In Phase 2 clinical trials, survodutide demonstrated up to 18.7% body weight loss at 46 weeks and remarkable liver fat reduction — with up to 87% of patients achieving MASH resolution and 64% achieving fibrosis improvement. The glucagon receptor component is key to its liver-specific benefits, as glucagon directly stimulates hepatic fat oxidation and reduces lipogenesis. Survodutide represents an important advancement in treating the growing epidemic of fatty liver disease, which affects approximately 25% of the global population.